Contineum Therapeutics, Inc.

SecurityCTNM / Contineum Therapeutics, Inc.
InstitutionSquarepoint Ops LLC
Latest Disclosed Ownership59,844 shares
Latest Disclosed Value $ 781,563
Squarepoint Ops LLC ownership in CTNM / Contineum Therapeutics, Inc.

On May 15, 2026 - Squarepoint Ops LLC filed a 13F-HR form disclosing ownership of 59,844 shares of Contineum Therapeutics, Inc. (US:CTNM) valued at $781,563 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 0 shares of Contineum Therapeutics, Inc.. The current value of the position is $746,853 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CONTINEUM THERAPEUTICS CL A 21217B100 59,844 59,844 782 0.0009
2026-02-13 2025-12-31 13F CONTINEUM THERAPEUTICS CL A 21217B100 0 -100.00 0
2025-11-14 2025-09-30 13F CONTINEUM THERAPEUTICS CL A 21217B100 13,086 -76,328 -85.36 154 -56.78 0.0002
2025-08-27 2025-06-30 13F/A-1 CONTINEUM THERAPEUTICS CL A 21217B100 89,414 -41,613 -31.76 355 -61.27 0.0004
2025-08-14 2025-06-30 13F CONTINEUM THERAPEUTICS CL A 21217B100 89,414 -41,613 355 0.0004
2025-08-27 2025-03-31 13F/A-1 CONTINEUM THERAPEUTICS CL A 21217B100 131,027 -86,212 -39.69 915 -71.28 0.0011
2025-05-15 2025-03-31 13F CONTINEUM THERAPEUTICS CL A 21217B100 131,027 -86,212 915 0.0011
2025-02-14 2024-12-31 13F CONTINEUM THERAPEUTICS CL A 21217B100 217,239 -132,761 -37.93 3,183 -52.50 0.0031
2024-11-14 2024-09-30 13F CONTINEUM THERAPEUTICS CL A 21217B100 350,000 200,000 133.33 6,699 153.65 0.0105
2024-08-14 2024-06-30 13F CONTINEUM THERAPEUTICS CL A 21217B100 150,000 150,000 2,642 0.0044
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.